Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of January 2014. The report serves to notify investors of the expiration of the Company's tradable Series 1 Warrants, which are listed on the Tel-Aviv Stock Exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding a specific security instrument rather than a financial performance report.
Material Changes
The primary material event is the impending expiration of the Series 1 Warrants. The filing states that unexercised warrants will be forfeited after the deadline, resulting in the loss of any rights or claims associated with them.
Guidance, Outlook, and Unusual Items
- Warrant Expiration: The Series 1 Warrants are exercisable until 9:00 Israel time on February 2, 2014.
- Exercise Terms: Each warrant is exercisable into one ordinary share.
- Exercise Price: The price is NIS 4.6, linked to the U.S. dollar exchange rate. Based on the rate published on January 28, 2011 ($1 = NIS 3.68), the equivalent U.S. dollar exercise price is $1.25.
- Adjustments: The actual NIS exercise price on the date of exercise will be determined by multiplying the $1.25 base by the representative NIS/USD exchange rate published by the Bank of Israel on that specific date, subject to adjustments per the 2011 Prospectus.
Investor Verification Checklist
- Verify the current market price of Redhill Biopharma ordinary shares against the $1.25 exercise price to determine if the warrants are in-the-money.
- Confirm the exact NIS/USD exchange rate published by the Bank of Israel on the intended exercise date to calculate the final exercise cost.
- Ensure any exercise requests are submitted to the Tel-Aviv Stock Exchange before the February 2, 2014, deadline to avoid forfeiture.
- Review the 2011 Prospectus for specific adjustment mechanisms that may alter the exercise price or share count.